Non-exclusive drug discount agreement for Calcipotriol/Betamethasone foam
Original notice title
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Calcipotriol/Betamethason - Schaum (amtlicher ATC-Code: D05AX22)
Opportunity Score
Why this score?
Opportunity
30 / 100
Complexity
20 / 100
Risk factors
No guaranteed demand; actual purchase volumes depend on prescription behavior and pharmacy stocking, which are unpredic...
Early termination possible if exclusive agreements are concluded (estimated 8-12 months after notice publication).
Deep Portfolio Analysis
Uses:
- Description
- Industries & Services
- Capabilities
- Market & Experience
- Certifications
Tender facts
- Contracting authority
- AOK PLUS - Die Gesundheitskasse für Sachsen und Thürigen
- Country
- Germany
- CPV
- 33600000 - Pharmaceutical products
- Deadline
- May 31, 2028
Overview
Moderate opportunityKey Facts
- Framework procurement
- Supplies contract
- 1 lot
- Duration until May 2028
- Conclusion of non-exclusive discount agreements for pharmaceutical product Calcipotriol/Betamethasone foam (ATC D05AX22)
- Agreement period from 4 May 2026 to 31 May 2028
Show full summary
This is an Open-House model for non-exclusive drug discount agreements for the active substance Calcipotriol/Betamethasone (ATC D05AX22) in foam form. The AOK PLUS invites pharmaceutical companies to conclude non-exclusive discount agreements under § 130a Abs. 8 SGB V. There is no estimated value, no guaranteed purchase volumes, and no exclusivity. Submission is possible from the first deadline (30 April 2026) until the final end of the agreement (31 May 2028). The procedure is not a formal procurement under EU directive but published for transparency.
Risks
No guaranteed demand; actual purchase volumes depend on prescription behavior and pharmacy stocking, which are unpredic...
Early termination possible if exclusive agreements are concluded (estimated 8-12 months after notice publication).
Analysis may be incomplete
Only part of the procurement documentation was analyzed. Additional eligibility requirements, certificates, or submission documents may exist in the remaining tender documentation.
Key Requirements
Technical
- Must be a pharmaceutical entrepreneur as defined in § 4 Abs. 18 AMG
Administrative
- Submission via DTVP communication function (not postal)
- Confidentiality of tender documents and discount terms
Requirements may be incomplete.
Buyer
Location
Dresden, DEU
Website
Buyer profile
Identifier
DE256878834
Activity
Health
Lots (1)
LOT-0001
Non-exclusive drug discount agreement for Calcipotriol/Betamethasone foam
Conclusion of non-exclusive discount agreements for Calcipotriol/Betamethasone foam (ATC D05AX22) via an Open-House model. No guaranteed volumes, no minimum purchase, no exclusivity. Agreement ends no later than 31 May 2028.
Location
Duration
Category
Deadline
Award details
Siehe Kurzbeschreibung
Value note
Show original TED data
Original lot title
Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Calcipotriol/Betamethason - Schaum (amtlicher ATC-Code: D05AX22)
Original TED description
Siehe Kurzbeschreibung
Procurement Details
- Publication date
- 26 Mar 2026
- Languages
- German
Reference metadata
- Legal basis
- 32014L0024
Reference IDs
- Tender ID
- 213144-2026
Documents (1)
Similar tenders
Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)
Germany – Pharmaceutical products – Abschluss nicht-exklusiver Rabattvereinbarungen nach § 130a Abs. 8 SGB V zu den genannten Wirkstoffen mit Abschlussmöglichkeit im Rahmen des sogenannten Open-House-Verfahrens.
Germany – Pharmaceutical products – Open House Biologika Rabattverträge 2026 - 27 - Follitropin delta
Opportunity Score
Why this score?
Opportunity
30 / 100
Complexity
20 / 100
Risk factors
No guaranteed demand; actual purchase volumes depend on prescription behavior and pharmacy stocking, which are unpredic...
Early termination possible if exclusive agreements are concluded (estimated 8-12 months after notice publication).
Deep Portfolio Analysis
Uses:
- Description
- Industries & Services
- Capabilities
- Market & Experience
- Certifications